Correlation of Serum Ethosuximide Levels with Clinical Effect

  • J. K. Penry


Correlation of clinical control with the serum concentration of phenobarbitone and phenytoin was reported for a group of patients by Buchthal and Svensmark (1959/ 1960) but wide use of serum concentrations did not begin until 1969 when Pippenger and Gillen reported the simultaneous, multiple determination of anti-epileptic drugs by gas-liquid chromatography. Subsequent to their report, the empirical improvement of seizure control by determining serum concentrations of anti-epileptic drugs has been widely used (Solow and Green, 1972; Green et al., 1973; Sherwin, Robb and Lechter, 1973). Nevertheless, skepticism remains among some physicians concerning the relationship of serum concentration to clinical effect because seizure frequency does not decrease in certain patients with high serum concentrations, even in the toxic range. Such patients are said to be refractory to the drug.


Serum Concentration Average Duration Seizure Frequency Seizure Control Absence Seizure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Browne, T. R., Dreifuss, F. E., Dyken, P. R., Goode, D. J., Penry, J. K., Porter, R. J., White, B. G., White, P. T.: Ethosuximide (Zarontin) in the treatment of absence (petit mal) seizures. Neurology 25, 515 (1975).PubMedGoogle Scholar
  2. Buchthal, F., Svensmark, O.: Aspects of the pharmacology of phenytoin (Dilantin) and phenobarbital relevant to their dosage in the treatment of epilepsy. Epilepsia 1, 373 (1959/1960).CrossRefGoogle Scholar
  3. Gastaut, H.: Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 11, 102 (1970).PubMedCrossRefGoogle Scholar
  4. Glazko, A. J., Dill, W. A.: Ethosuximide: Chemistry and methods for determination. In: Antiepileptic Drugs (eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt), p. 413, New York: Raven Press 1972.Google Scholar
  5. Green, J. B., Hartlage, L., Solow, E., Baum, E.: Correlations between seizure frequency and serum anticonvulsant levels. Neurology 23, 405 (1973).Google Scholar
  6. Penry, J. K., Porter, R. J., Dreifuss, F. E.: Ethosuximide: Relation of plasma levels to clinical control. In: Antiepileptic Drugs (eds. D. M. Woodbury, J. K. Penry, R. P. Schmidt), p. 431. New York: Raven Press 1972.Google Scholar
  7. Pippenger, C. E., Gillen, H. W.: Gas chromatographic analysis for anti-convulsant drugs in biological fluids. Clin. Chem. 15, 582 (1969).PubMedGoogle Scholar
  8. Sherwin, A. L., Robb, J. P., Lechter, M.: Improved control of epilepsy by monitoring plasma ethosuximide. Arch. Neurol. 28, 178 (1973).PubMedCrossRefGoogle Scholar
  9. Solow, E. B., Green, J. B.: The simultaneous determination of multiple anticonvulsant drug levels by gas-liquid chromatography. Neurology 22, 540 (1972).PubMedGoogle Scholar
  10. Triedman, H. M., Fishman, R. A., Yahr, M. D.: Determination of plasma and cerebrospinal fluid levels of Dilantin in the human. Trans. Amer. Neurol. Ass. 85, 166 (1960).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin-Heidelberg 1975

Authors and Affiliations

  • J. K. Penry
    • 1
  1. 1.Applied Neurologic Research Branch, Collaborative and Field Research, National Institute of Neurological Diseases and StrokeNational Institutes of HealthBethesdaUSA

Personalised recommendations